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ABSTRACT 
Glaucoma is a chronic disease that causes irreversible blindness. Timolol Maleate is used as first line drug in treatment of glaucoma. 
Poor ocular bioavailability and therapeutic response shown by conventional ophthalmic system can be overcome by use of in situ 
gelling system which undergoes reversible sol to gel transition in cul-de-sac by physical stimulation. Present work describes 
formulation and evaluation of pH sensitive in situ gel system of Timolol Maleate. Carbopol 974P was used as pH sensitive polymer 
with HPMC K15M as viscosity modifier. 32 factorial design was used to study the effect of independent variables viz. concentrations 
of Carbopol 974P and HPMC K15M on dependent variables like in vitro drug diffusion and viscosity. Optimized batch showed 
88.48% drug diffusion upto 8h. Optimized formulation was evaluated for various parameters such as drug release study, isotonicity, 
texture analysis, preservative efficacy studies, sterility testing as per IP 2010, accelerated stability studies. Ex vivo transcorneal 
permeability study was carried out on goat eye cornea which showed that EDTA (0.5%) increases drug penetration by 1.90 fold and 
showed no corneal damage after histological study. In conclusion, prepared formulation is stable and non-irritant. 
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INTRODUCTION: 
Glaucoma is a chronic disease of eye that is 
characterized by irreversible damage to the ganglionic 
cells and the optic nerve. Elevated intraocular pressure 
is most important risk factor for glaucoma. It has been 
established as the second leading cause of world’s 
blindness, which may affect around 80 million in 2020. 
The treatment of glaucoma focuses mainly on lowering 
of IOP. In the last two decades several classes of topical 
IOP lowering drugs have been made available which 
includes beta blocker, prostaglandin analogue (PGA), 
alpha-adrenoceptor agonist (AA) and topical carbonic 
anhydrase inhibitors (CAI's). 
Timolol Maleate (TM) is a non-selective beta-adrenergic 
receptor blocker used in treatment of open angle 
glaucoma and occasionally in secondary glaucoma. 
Conventionally it is available in the form of solution 
which gets immediately eliminated from the precorneal 
area. Further, shorter contact time with poor corneal 
permeability results into poor bioavailability (10%) and 
decreased patient compliance. Several novel drug 
delivery systems (NDDS’s) have been developed which 
includes inserts, ointment, nanosuspension etc. However 
these systems suffer from several drawbacks such as 
blurred vision associated with ointment, low patient 
compliance from inserts and high cost of nano 
suspension. These problems can be overcome by using 
in situ gel forming systems. 
In situ drug delivery systems consist of polymers that 
exhibit sol to gel phase transition in cul-de-sac by 
several physicochemical parameters.  Depending upon 
method used for sol to gel phase transition three types of 
in situ gels are widely accepted as pH triggered system, 
ion activated system and temperature dependent system. 
Pharmaceutically significant gels can be prepared by 
using various materials. Carbopol 974P is pH sensitive 
polymer which shows sol to gel transition in aqueous 
solution when pH is raised above 5.5. It is polyacrylic 
acid (PAA) which is required in high concentration to 
form stiff gel. At higher concentration it forms highly 
acidic solution which is not easily neutralized by buffer 
action of tear fluid. Reduction in its concentration 
without affecting the gelling capacity and viscosity was 
achieved by addition of viscosity increasing polymers 
such as HPMC. 
MATERIAL AND METHODS:  
Material 
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Timolol Maleate and Carbopol 974P were gifted by 
FDC Limited, Mumbai and Lubrizol advanced material 
India Pvt. Ltd., Mumbai respectively. HPMC K15M was 
purchased from S. D. Fine, Mumbai. HPLC grade 
methanol was purchased from Qualigens Fine 
chemicals, Mumbai. All other ingredients were of 
analytical grade. IOTIM (Timolol Maleate eye drops 
0.5% by FDC) was brought from local medical shop.  
Analytical method development  
To quantitate the content of Timolol Maleate in samples 
reversed phase (RP)-HPLC method was developed and 
validated as per ICH guidelines Q2 (R1). Shimadzu RP-
HPLC instrument (CFR-21) equipped with photodiode 
array detector (PDA) and C18 column of Kromasil (250 
mm × 4.6 mm, 5µm particle size) was used. Mobile 
phase consisted of phosphate buffer: methanol (60:40 
v/v) and pH 3.5 was maintained by O-phosphoric acid. 
Elution was measured at 295 nm with flow rate of 1.0 
ml/min. 
Full factorial experimental design 
For optimization of Timolol Maleate in situ gel, 3
2
 
randomized full factorial design was selected. The 
design was applied to study the effect of concentration 
of Carbopol 974P and HPMC K15M on formulation. 
The amount (%) of pH sensitive polymer, Carbopol 
974P (X1) and the amount (%) of viscosity modifier, 
HPMC K15M (X2) were selected as independent 
variables, in this study. These two factors were 
evaluated at 3 levels as higher, middle and lower levels. 
Composition of different batches of Timolol Maleate is 
shown in table 1.  
Evaluation of formulation  
Formulation was evaluated for various parameter viz. 
physicochemical evaluation, viscosity, drug diffusion, 
ex-vivo transcorneal permeation, histological evaluation, 
in-vitro drug release, isotonicity, texture analysis, 
sterility, preservative efficacy study and accelerated 
stability study. 
  
Table 1: Composition of different batches of Timolol Maleate in situ gel 
 
Name of excipients  
Different batches of Timolol Maleate in situ gel (%w/v) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
          
Timolol Maleate 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 
Sodium Chloride 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
Carbopol  974P 0.15 0.15 0.15 0.30 0.30 0.30 0.45 0.45 0.45 
HPMC K15M 0.25 0.50 0.75 0.25 0.50 0.75 0.25 0.50 0.75 
Benzalkonium chloride 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 
Water q.s. 100 100 100 100 100 100 100 100 100 
 
RESULTS AND DISCUSSION: 
The pH triggered Timolol maleate in situ gel was 
successfully formulated by using Carbopol 974P and 
HPMC K15M. Formulation was optimized by 
3
2
randomised full factorial design for two responses viz. 
viscosity at 20 rpm and cumulative percent drug 
diffused at the end of 8 h. Optimized formulation (Batch 
f7) was liquid at pH 4 and gel above pH 7 indicating in 
situ transition at physiological pH. Optimized in situ gel 
passes all safety tests used for evaluation of ophthalmic 
formulation as per regulatory guidelines. In vitro drug 
release study showed sustained release of drug from in 
situ gel over period of 8h as compared to marketed 
formulation IOTIM (FDC). Prepared formulation was 
subjected for ex vivo transcorneal permeability study 
and result was compared with IOTIM which showed 
need of penetration enhancer. EDTA (0.5% w/v) was 
found to be suitable penetration enhancer which showed 
significant increase in transcorneal permeability of drug 
(Fig. 1). Formulation showed less eye irritation as 
compared to SDS (positive control) during histological 
study on goat eye cornea (Fig. 2). Stability study 
performed over a period of 3 month showed that 
optimized formulation is stable. Hence; prepared 
formulation is feasible alternative for conventional eye 
drop for glaucoma treatment but future in vivo studies 
on human is necessary to confirm significant therapeutic 
effect.  
 
Figure 1: Comparative ex vivo transcorneal cumulative 
% drug release
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Figure 2: Histological section of goat eye cornea (magnification 40X) a) negative control: untreated cornea, b) test 
specimen: formulation treated cornea, c) positive control: SDS treated cornea for 5h. 
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